JP2024521792A5 - - Google Patents

Info

Publication number
JP2024521792A5
JP2024521792A5 JP2023572828A JP2023572828A JP2024521792A5 JP 2024521792 A5 JP2024521792 A5 JP 2024521792A5 JP 2023572828 A JP2023572828 A JP 2023572828A JP 2023572828 A JP2023572828 A JP 2023572828A JP 2024521792 A5 JP2024521792 A5 JP 2024521792A5
Authority
JP
Japan
Application number
JP2023572828A
Other languages
Japanese (ja)
Other versions
JP2024521792A (ja
JPWO2022251484A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031115 external-priority patent/WO2022251484A1/en
Publication of JP2024521792A publication Critical patent/JP2024521792A/ja
Publication of JP2024521792A5 publication Critical patent/JP2024521792A5/ja
Publication of JPWO2022251484A5 publication Critical patent/JPWO2022251484A5/ja
Pending legal-status Critical Current

Links

JP2023572828A 2021-05-26 2022-05-26 補体媒介性疾患の治療法 Pending JP2024521792A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193573P 2021-05-26 2021-05-26
US63/193,573 2021-05-26
PCT/US2022/031115 WO2022251484A1 (en) 2021-05-26 2022-05-26 Treatment of complement-mediated disorders

Publications (3)

Publication Number Publication Date
JP2024521792A JP2024521792A (ja) 2024-06-04
JP2024521792A5 true JP2024521792A5 (https=) 2025-06-02
JPWO2022251484A5 JPWO2022251484A5 (https=) 2025-06-02

Family

ID=84229204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572828A Pending JP2024521792A (ja) 2021-05-26 2022-05-26 補体媒介性疾患の治療法

Country Status (4)

Country Link
US (1) US20250002910A1 (https=)
EP (1) EP4346844A4 (https=)
JP (1) JP2024521792A (https=)
WO (1) WO2022251484A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
WO2022226127A1 (en) * 2021-04-20 2022-10-27 Alexion Pharmaceuticals, Inc. Compositions and methods for inhibiting complement component 3 expression
CN120265773A (zh) * 2022-10-14 2025-07-04 美国圣因生物股份有限公司 靶向c3的小干扰rna及其用途
EP4600358A1 (en) * 2023-04-14 2025-08-13 Rigerna Therapeutics (Suzhou) Co., Ltd. Compound for inhibiting c3 gene expression, pharmaceutical composition and use thereof
AU2024312039A1 (en) * 2023-06-21 2026-01-22 Changzhou Hansoh Pharmaceutical Co., Ltd. Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof
CN117050998B (zh) * 2023-08-25 2024-02-09 青岛农业大学 一种miRNA在防治溴氰虫酰胺抗性烟粉虱中的应用
JPWO2025143000A1 (https=) * 2023-12-27 2025-07-03
WO2025168134A1 (zh) * 2024-02-08 2025-08-14 北京安龙生物医药有限公司 靶向补体成分c3基因的寡核苷酸及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019113301A (ru) * 2016-10-17 2020-11-17 Апеллис Фармасьютикалс, Инк. Комбинированная терапия для ингибирования с3
AU2018360697A1 (en) * 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024515344A5 (https=)
BR102022025291A2 (https=)
JPWO2025143000A1 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13160U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13175U (https=)
BY13174U (https=)